After a lacklustre full year results released in March 2017, the growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceuticals, biotechnology and medical device clients today provided a trading update for the six months ended 30 June 2017. The new financial year started well with the Company securing contract wins in January and February with a value of €5.7m. Total revenues for the Company were ahead compared to
20 Jul 2017
Solid H1 2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid H1 2017
hVIVO plc (HVO:LON) | 26.5 -0.2 (-2.8%) | Mkt Cap: 180.3m
- Published:
20 Jul 2017 -
Author:
Darshan Patel -
Pages:
6
After a lacklustre full year results released in March 2017, the growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceuticals, biotechnology and medical device clients today provided a trading update for the six months ended 30 June 2017. The new financial year started well with the Company securing contract wins in January and February with a value of €5.7m. Total revenues for the Company were ahead compared to